TNF and hydrops fetalis: Extensive studies involving TNF-α antagonism that use etanercept as well as infliximab in a group of large-scale clinical trials have not demonstrated any benefit for chronic HF patient populations, further exemplifying the intricacy behind the inflammatory mechanism involved.